Main menu
Features
Webinars
Icon Library
Pricing
Learning Hub
Testimonials
Sign in
Sign up free

COVID-19 Vaccine & Therapeutics Tracker

See the latest updates for vaccine and therapeutic drug developments for COVID-19. Check back for regular updates!
New addition counters are reset every Monday by 11:59 PM ET. Last updated April 5, 2021 at 11:07AM ET
Vaccines
216
+6
TOTAL
92
+6
IN HUMAN TRIALS
Therapeutic Drugs
506
+1
TOTAL
419
+1
IN HUMAN TRIALS
Activity FeedLive updates on vaccine and therapeutic drug developments
The ERUCOV-VAC vaccine enters phase 2 clinical trials in the Republic of Turkey.
April 1, 2021
Boehringer Ingelheim’s SARS-CoV-2 neutralizing antibody, BI 767551 , enters phase 2/3 clinical trials.
March 30, 2021
Daiichi Sankyo Co., Ltd.’s mRNA vaccine, DS-5670a , enters phase 1/2 clinical trials in Japan.
March 29, 2021
The Scientific and Technological Research Council of Turkey’s SARS-CoV-2 VLP Vaccine enters phase 1 clinical trials.
March 26, 2021
ReCOV , the two-component recombinant protein vaccine developed by the Jiangsu Rec-Biotechnology Co., Ltd, enters phase 1 clinical trials in New Zealand.
March 26, 2021
AZD1222 (ChAdOx1 nCoV-19) had a 76 percent efficacy rate at preventing symptomatic illness in a new analysis of its major clinical trial in the United States of America which is slightly lower than the level announced earlier this week in a report that was criticized for using outdated information.
March 25, 2021
ZHONGYIANKE Biotech Co, Ltd.’s recombinant protein vaccine enters phase 2 clinical trials in China.
March 24, 2021
ModernaTX, Inc.’s new refrigerator-stable vaccine, mRNA-1283 , starts phase 1 clinical trials in the United States of America.
March 24, 2021
Casirivimab/Imdevimab reduced hospitalization or death by 70% in non-hospitalized patients with COVID-19 and retain activity against key emerging variants according to a press release of phase 3 clinical trial data by Roche.
March 23, 2021
Genexine, Inc.’s efineptakin alfa single treatment (GX-17) enters phase 2 clinical trials.
March 23, 2021
The University of Hong Kong’s live attenuated influenza vaccine, DelNS1-nCoV-RBD LAIV , enters phase 1 clinical trials.
March 22, 2021
The AZD1222 (ChAdOx1 nCoV-19) vaccine phase 3 clinical trial met the primary efficacy endpoint in preventing COVID-19 at interim analysis with 79% vaccine efficacy at preventing symptomatic infection, 100% efficacy against severe or critical disease and hospitalization, comparable efficacy result across ethnicity and age, and favourable reactogenicity and overall safety profile according to a press release by AstraZeneca.
March 22, 2021
AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) vaccine is not associated with an increase in the overall risk of blood clots according to a press release by the European Medicines Agency.
March 18, 2021
The AZD1222 (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate COVID-19 due to the B.1.351 variant according to a publication in The New England Journal of Medicine of phase 1/2 clinical trial results.
March 16, 2021
MV-014-212 , the live-attenuated respiratory syncytial virus vector vaccine depveloped by Meissa Vaccines, Inc., starts phase 1 clinical trials in The United States of America.
March 15, 2021
Sanofi Pasteur’s mRNA vaccine starts phase 1/2 clinical trials in the United States of America.
March 15, 2021
Novavax’s NVX-CoV2373 demonstrated 100% protection against severe disease, 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain, and 55.4% efficacy in a region where the vast majority of strains are B1.351 escape variants according to a press release of their phase 3 U.K. and phase 2b South Africa clinical trial studies, respectively.
March 11, 2021
Johnson and Johnson’s single-dose vaccine, Ad26.COV2.S , is approved by The European Medicines Agency for use in the European Union.
March 11, 2021
New data show Bamlanivimab plus Etesevimab therapy reduced the risk of hospitalizations and death by 87 percent in high-risk patients recently diagnosed with COVID-19, according to a press release about the randomized, double-blind, placebo-controlled phase 3 study.
March 10, 2021
New data show Bamlanivimab plus Etesevimab therapy reduced the risk of hospitalizations and death by 87% in high-risk patients recently diagnosed with COVID-19, according to a press release about the randomized, double-blind, placebo-controlled phase 3 study.
March 10, 2021
VIR-7831 as monotherapy demonstrated an 85% reduction in hospitalization or death in adults with early COVID-19 compared to placebo according to a press release of preliminary results from a phase 3 clinical trial.
March 10, 2021
COVID-eVax , a DNA plasmid-based vaccine developed by Takis and Rottapharm Biotech, enter phase 1/2 clinical trials in Italy.
March 9, 2021
Covaxin , a whole-virion inactivated SARS-CoV-2 vaccine developed by Bharat Biotech International, induced high neutralising antibody titres and enhanced cell-mediated immune responses, as well as tolerable safety outcomes according to a publication in The Lancet journal of their phase 1 and 2 clinical trials.
March 8, 2021
EuCorVac-19 , a protein subunit vaccine developed by EuBiologics Co., enters phase 1/2 clinical trial in the Republic of Korea.
March 5, 2021
SpFN COVID-19 , a protein subunit vaccine developed by the United States Army Medical Research and Development Command, enters phase 1 clinical trial in the United States of America.
March 5, 2021
Johnson and Johnson’s single-shot vaccine, Ad26.COV2.S , has been approved by Health Canada.
March 5, 2021
Ivermectin did not significantly improve the time to resolution of symptoms among adults with mild COVID-19 according to a placebo-controlled, randomized clinical trial published in the Journal of the American Medial Association.
March 4, 2021
The European Medicines Agency starts a rolling review of the Sputnik V (Gam-COVID-Vac) COVID-19 vaccine.
March 4, 2021
SARS-CoV-2 B.1.1.7 was shown to be sensitive to neutralization by serum samples from convalescent individuals and recipients of mRNA-1273 and Novavax vaccines indicating that this variant is unlikely to be a major concern for current vaccines according to a publication in the journal Cell Host & Microbe.
March 3, 2021
SARS-CoV-2 B.1.1.7 was shown to be sensitive to neutralization by serum samples from convalescent individuals and recipients of mRNA-1273 and NVX-CoV2373 vaccines indicating that this variant is unlikely to be a major concern for current vaccines according to a publication in the journal Cell Host & Microbe.
March 3, 2021
Covaxin demonstrated 81% interim efficacy in preventing COVID-19 in those without prior infection after the second dose according to a press release by Bharat Biotech.
March 3, 2021
The protein subunit vaccine EpiVacCorona enters phase 3 clinical trials in Russia.
March 3, 2021
Vaccination with either a single dose of Comirnaty (BNT162b2) or AZD1222 (ChAdOx1 nCoV-19) was associated with a significant reduction in symptomatic SARS-CoV-2 positive cases in older adults with even greater protection against severe disease and a second dose of the former provides further protection against symptomatic disease according to a publication in the preprint server medRxiv by Public Health England.
March 2, 2021
Two new COVID-19 vaccines, ChAdV68-S and SAM-LNP-S , developed by the United States National Institute of Allergy and Infectious Diseases enter phase 1 clinical trials.
March 1, 2021
Johnson and Johnson’s single-shot vaccine, Ad26.COV2.S , has been approved for emergency use by The United States of America Food and Drug Administration.
February 27, 2021
VBI-2902a, a new virus-like particle vaccine developed by VBI Vaccines Inc., enters phase 1/2 clinical trials in Canada.
February 26, 2021
Health Canada approves the use of AstraZeneca and The University of Oxford’s AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine.
February 26, 2021
The United States Food and Drug Administration allows Pfizer and BioNTech’s Comirnaty (BNT162b2) to be transported/stored for up to two weeks at standard freezer temperatures.
February 25, 2021
Moderna, Inc. announces that it has completed manufacturing of its variant-specific vaccine candidate, mRNA-1273 .351, against the SARS-CoV-2 variant B.1.351 and has shipped doses to the National Institutes of Health for a Phase 1 clinical trial.
February 24, 2021
Proxalutamide significantly accelerated viral clearance and time to clinical remission in mild to moderate COVID-19 patients versus placebo according to a randomized, double-blinded, placebo-controlled trial published in the journal Cureus.
February 22, 2021
The Newcastle disease vector vaccine, NDV-HXP-S, enters phase 1 clinical trials in Thailand.
February 21, 2021
Providence Therapeutic’s mRNA vaccine, PTX-COVID19-B , enters phase 1 clinical trials in Canada.
February 21, 2021
Intravenous Ivermectin demonstrated a significant reduction in days to COVID negativity in mild to moderate COVID19 patients according to a randomized controlled double-blind study in the Quarterly Journal of Medicine.
February 18, 2021
A second COVID-19 vaccine developed by SK Bioscience's, NBP2001 , enters phase 1 clinical trials in the Republic of Korea.
February 18, 2021
A novel inactivated SARS-CoV-2 vaccine, Unnamed Inactive Vaccine - Jiangsu , developed by Beijing Minhai Biotechnology Co., Shenzhen Kangtai Biological Products Co., and the Jiangsu Province Centers for Disease Control and Prevention enters phase 1/2 clinical trials in China.
February 17, 2021
GlaxoSmithKline’s RNA vaccine, CoV2 SAM (LNP) , enters phase 1 clinical trials in The United States of America.
February 17, 2021
Pfizer’s oral antiviral clinical candidate, PF-07321332 , enters phase 1 clinical trial in the United States of America.
February 16, 2021
BBV154 , an intranasally delivered adenovirus-vector vaccine developed by Bharat Biotech International Limited, enters phase 1 clinical trials in India.
February 12, 2021
Zinc and Vitamin C alone or in combination did not significantly decrease the duration of COVID-19 symptoms compared with standard of care in a randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection published in JAMA Network Open.
February 12, 2021
AZD1222 (ChAdOx1 nCoV-19) did not show protection against mild-moderate COVID-19 due to the SARS-CoV-2 South African variant (B.1.351), however, efficacy against severe COVID-19 was undetermined according to a publication in the preprint server medRxiv.
February 12, 2021
Tocilizumab reduced the risk of death, shortened the time to hospital discharge, and reduced the need for a mechanical ventilator when given to hospitalized patients with severe COVID-19 according to the United Kingdom’s RECOVERY Trial.
February 11, 2021
COVIGEN , the needle-free DNA COVID-19 vaccine by BioNet enters phase 1 clinical trials in Australia.
February 8, 2021
SK Bioscience’s COVID-19 vaccine, GBP510 , enters phase 1/2 clinical trial in the Republic of Korea.
February 8, 2021
Comirnaty (BNT162b2) -elicited antibodies were shown to neutralize the B.1.1.7 SARS-CoV-2 variant in a preprint publication bioRxiv.
February 7, 2021
CoronaVac had an efficacy rate against diseases caused by COVID-19 of 50.65% for all cases, 83.70% for cases requiring medical treatment, and 100% for hospitalized, severe, and fatal cases according to a press release by the company of their Phase 3 clinical trials result.
February 5, 2021
Efficacy of AZD1222 (ChAdOx1 nCoV-19) against the B.1.1.7 variant of SARS-CoV-2 is similar to that of other lineages and vaccination reduces the duration of shedding and viral load according to a preprint publication in The Lancet.
February 4, 2021
Methylprednisolone was better than Dexamethasone in treating hospitalized hypoxic COVID-19 patients according to a preprint publication in the journal BMC Infectious Disease.
February 1, 2021
Johnson and Johnson’s single-dose vaccine, Ad26.COV2.S , was shown to be 66% and 85% effective overall at preventing moderate to severe COVID-19 and in preventing severe disease, respectively, and demonstrated complete protection against COVID-19 related hospitalization and death 28 days after vaccination according to a press release about their phase 3 clinical trial.
January 29, 2021
Novavax’s COVID-19 Vaccine, NVX-CoV2373 , Demonstrated 89.3% Efficacy in their phase 3 clinical trial according to a company press release.
January 28, 2021
Pfizer and BioNTech’s Comirnaty (BNT162b2) vaccine generates antibodies that neutralize the new South African SARS-CoV-2 variant B.1.351 according to a publication in the preprint server bioRxiv.
January 27, 2021
Eli Lilly’s neutralizing antibodies Bamlanivimab and Etesevimab together reduced risk of COVID-19 hospitalizations and death by 70% according to phase 3 clinical trial results released by the company.
January 26, 2021
Regeneron‘s Casirivimab/Imdevimab antibody cocktail was 100% effective at preventing symptomatic infection and had approximately 50% lower overall rates of infection when used as a passive vaccine for the prevention of COVID-19 in people at high risk of infection according to a press release of interim data from their phase 3 clinical trial.
January 26, 2021
Azithromycin and Doxycycline were shown to have no beneficial effect in patients aged over 50 who are treated with either antibiotic at home in the early stages of COVID-19 following interim analyses of data from the University of Oxford’s PRINCIPLE trial.
January 25, 2021
Moderna’s vaccine, mRNA-1273 , induces neutralizing antibodies against global SARS-CoV-2 variants from the United Kingdom (B.1.1.7) and South Africa (B.1.351), according to a publication in the preprint server bioRxiv.
January 25, 2021
Eli Lilly's neutralizing antibody Bamlanivimab prevented COVID-19 at nursing homes, reducing risk by up to 80 percent according to a press release of preliminary data from their phase 3 clinical trial.
January 21, 2021
Tocilizumab was not superior to standard care alone in patients with severe or critical COVID-19, and it might increase mortality, according to phase 3 clinical trial results published in the British Medical Journal.
January 20, 2021
Pfizer and BioNTech’s Comirnaty (BNT162b2) vaccine generates antibodies that neutralize the new SARS-CoV-2 variant B.1.1.7 according to a publication in the preprint server bioRxiv.
January 19, 2021
Sinovac Biotech’s CoronaVac vaccine was 50.4 percent effective at preventing symptomatic infections according to further analysis of their phase 3 clinical trial in Brazil, significantly less than earlier reported (78%).
January 13, 2021
Johnson and Johnson’s Ad26.COV2.S was shown to be safe and elicit both an antibody and cell-mediated immune response according to an interim analysis of their phase 1/2 clinical trial published in The New England Journal of Medicine.
January 13, 2021
The University of Saskatchewan’s COVID19 vaccine, COVAC-2 , enters phase 1/2 clinical trials in Canada.
January 8, 2021
Medigen Vaccine Biologics Corp.’s COVID19 vaccine, MVC-COV1901 , enters phase 2 clinical trials in Taiwan and Vietnam.
January 5, 2021
The Republic of India approves the use of AstraZeneca and The University of Oxford’s SARS-CoV-2 vaccine, AZD1222 (ChAdOx1 nCoV-19) .
January 4, 2021
The Republic of India approves the use of Bharat Biotech’s SARS-CoV-2 vaccine, Covaxin .
January 3, 2021
The Republic of Turkey’s inactive vaccine, ERUCOV-VAC , enters phase 1 clinical trials.
January 1, 2021
The Republic of Khazakstan’s QazCovid-in COVID19 vaccine enters phase 3 with an expected 3000 participants.
December 31, 2020
AZD1222 (ChAdOx1 nCoV-19) , the coronavirus vaccine developed jointly by Oxford University and AstraZeneca, is approved for use in The United Kingdom.
December 30, 2020
Treatment with Regeneron’s Casirivimab/Imdevimab lowers the risk of death or receiving mechanical ventilation according to a press release of initial data from phase 1/2/3 clinical trial in hospitalized COVID-19 patients requiring low-flow oxygen who have yet to mount their own immune response to SARS-CoV-2.
December 29, 2020
In a press release, Arcturus Therapeutics announced phase 1/2 clinical trial data demonstrating favorable tolerability and immunogenicity in 100% (44/44) of LUNAR-COV19 (ARCT-021) vaccinated subjects.
December 28, 2020
The Results of Inovio Pharmaceuticals’s DNA vaccine phase 1 clinical trial published in the journal EClinicalMedicine indicates that INO-4800 demonstrated excellent safety and tolerability and was immunogenic in 100% (38/38) of the vaccinated subjects.
December 24, 2020
A new spike protein vaccine, Nanocovax , enters phase 1/2 in Vietnam.
December 24, 2020
COVAXX’s protein antigen vaccine, UB-612 , enters phase 2/3 clinical trials.
December 24, 2020
AKS-452 , a new protein vaccine against SARS-CoV-2, developed by Akston Biosciences Corporation enters phase 1/2 clinical trials in the Netherlands.
December 23, 2020
Health Canada approves Moderna’s COVID-19 vaccine, mRNA-1273 .
December 23, 2020
AltImmune’s replication-deficient adenovirus type 5 based vaccine, AdCOVID , enters phase 1 clinical trials in The United States of America.
December 23, 2020
The Results of Bharat Biotech’s inactive SARS-CoV-2 vaccine phase 2 clinical trial published in the preprint server medRxiv reveals Covaxin had tolerable safety outcomes and enhanced humoral and cell-mediated immune responses.
December 22, 2020
The Results of Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. protein subunit vaccine phase 1/2 clinical trial published in the preprint server medRxiv reveals ZF2001 was well-tolerated and immunogenic.
December 22, 2020
Takeda’s TAK-919 vaccine enters phase 1/2 clinical trials in Japan.
December 21, 2020
The European Medical Agency recommends Pfizer and BioNTech’s Comirnaty (BNT162b2) COVID-19 vaccine for authorisation in the European Union.
December 21, 2020
Alpha-1 antitrypsin treatment of Hospitalized Patients With Pneumonia and COVID-19 Infection enters phase 3 clinical trials in The United States of America.
December 19, 2020
Moderna’s mRNA-1273 was approved by the United States Food and Drug Administration.
December 18, 2020
Clover Biopharmaceuticals SCB-2019 vaccine enters phase 2/3 clinical trials.
December 17, 2020
GeneOne Life Science, Inc.’s DNA vaccine, GLS-5310 , enters phase 1/2 clinical trials in South Korea.
December 17, 2020
Valneva Austria GmbH’s inactive vaccine, VLA2001 , enters phase 1/2 clinical trials in the United Kingdom.
December 16, 2020
Azithromycin was shown to have no benefit in patients hospitalised with COVID-19 according to preliminary analysis of RECOVERY trial patients.
December 14, 2020
Cellid Co., Ltd.’s adenovirus-based vaccine, AdCLD-CoV19 , enters phase 1/2 clinical trials in South Korea.
December 14, 2020
Pfizer and BioNTech’s Comirnaty (BNT162b2) is approved for use in Canada.
December 9, 2020
The unnamed inactivated SARS-CoV-2 vaccine developed by the Chinese Academy of Medical Sciences enters phase 3 in China with an expected enrollment of over 34,000 individuals.
December 9, 2020
First doses of Pfizer’s Comirnaty (BNT162b2) administered in the United Kingdom.
December 8, 2020
AG0302-COVID19 , AnGes, Inc.’s second COVID-19 vaccine enters phase 2/3 clinical trials in Japan.
December 7, 2020
Bamlanivimab enters phase 4 clinical trials with an at-home infusion regimen in the United States of America.
December 7, 2020
Sputnik V (Gam-COVID-Vac) starts phase 3 clinical trials in the United Arab Emerates.
December 7, 2020
CureVac AG’s CVnCoV enters phase 3 clinical trials in Germany.
December 3, 2020
Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon regimens had little or no effect on hospitalized patients with COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay according to Interim WHO Solidarity Trial Results published in the New England Journal of Medicine.
December 2, 2020
The United Kingdom becomes the first country in the world to approve the Pfizer and BioNTech vaccine, Comirnaty (BNT162b2) , for emergency use in its population.
December 2, 2020
ZF2001 , the recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters phase 3 clinical trials in China.
November 30, 2020
Moderna’s mRNA-1273 vaccine efficacy against COVID-19 was 94.1% overall and 100% against severe COVID-19 according to a press release detailing their primary efficacy analysis of the Phase 3 COVE study.
November 30, 2020
AbbVie’s investigational anti-SARS-CoV-2 monoclonal antibody, ABBV-47D11 , enters phase 1 clinical trials.
November 25, 2020
Sinocelltech Ltd.’s recombinant anti-SARS-CoV-2 spike protein monoclonal antibody, SCTA01 , enters phase 2/3 clinical trials.
November 25, 2020
Inovio Pharmaceuticals INO-4800 enters phase 2/3 clinical trials in the United States of America.
November 24, 2020
Ivermectin was shown to reduce the rate of mortality, low oxygen duration, and duration of hospitalization in adult COVID 19 patients in a preprint randomized, double-blind, placebo-controlled, multicenter, phase 2 clinical trial study of 180 mild to severe hospitalized individuals.
November 24, 2020
The Russian Sputnik V (Gam-COVID-Vac) enters phase 3 clinical trials in Venezuela.
November 24, 2020
Sputnik V (Gam-COVID-Vac) demonstrates 91.4% efficacy after 28 days (n=18,794) and 95% efficacy 21 days after the second dose according to the second interim analysis of clinical trials data in a press release from the Gamaleya Center team.
November 24, 2020
Interim analysis of clinical trials of AZD1222 (ChAdOx1 nCoV-19) demonstrates 90% when given as a half dose, followed by a full dose (n=8,895), and 62% efficacy when given as two full doses (n=11,636) for an average efficacy of 70% according to a press release by AstraZeneca.
November 23, 2020
Baricitinib, Dexamethasone, and Remdesivir will be tested through the National Institute of Allergy and Infectious Diseases’ phase 3 clinical trial named ACTT-4.
November 23, 2020
The Russian Sputnik V (Gam-COVID-Vac) enters phase 2/3 clinical trials in the Republic of India.
November 23, 2020
The Unnamed Recombinant Vaccine - Jiangsu from Jiangsu Province Centers for Disease Control and Prevention and West China Hospital enter phase 2 clinical trials in China.
November 23, 2020
Covaxin , Bharat Biotech International Limited’s whole, inactive SARS-CoV-2 virus particle-based vaccine, enters phase 3 in the Republic of India, with an expected enrollment of 25,800 participants.
November 23, 2020
The United States Food and Drug Administration issued an emergency use authorization for Casirivimab/Imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
November 21, 2020
The City of Hope Medical Center and National Cancer Institue’s synthetic modified vaccinia Ankara-based vaccine, COH04S1 , enter phase 1 clinical trials in the United States of America.
November 20, 2020
Medicago’s virus-like particle vaccine, CoVLP , enters phase 2/3 clinical trials with expected recruitment of over 30,000 participants.
November 19, 2020
Pfizer and BioNTech concluded Phase 3 study for their RNA-based vaccine, Comirnaty (BNT162b2) , with 95% efficacy against COVID-19 and good tolerance across all tested demographics.
November 18, 2020
Moderna’s mRNA-1273 COVID-19 vaccine is 94.5% effective according to first interim analysis of its phase 3 study.
November 16, 2020
CORVax , a new DNA plasmid vaccine enters phase 1 clinical trials in The United States of America.
November 13, 2020
Patients treated with Fluvoxamine had a lower likelihood of clinical deterioration compared to placebo controls in a preliminary study of adult outpatients with symptomatic COVID-19 according to a publication in The Journal of the American Medical Association.
November 12, 2020
Bamlanivimab has been granted emergency use authorization by the U.S. Food and Drug Administration for patients recently diagnosed with COVID-19.
November 9, 2020
Positive phase 3 study interim results were announced for Pfizers and BioNTech’s RNA-based vaccine, Comirnaty (BNT162b2) , with >90% efficacy in preventing COVID-19 across study participants.
November 9, 2020
AstraZeneca’s long-lasting antibody treatment against COVID-19, AZD7442 , enters phase 3 clinical trials.
November 9, 2020
A new live-attenuated vaccine against COVID-19, COVI-VAC , starts phase 1 clinical trials in the United Kingdom.
November 6, 2020
CT-P59 treatment resulted in at least 44% faster recovery time when compared with placebo control in phase 1 clinical trial results of COVID-19 patients with mild symptoms
November 6, 2020
Johnson and Johnson extends Ad26.COV2.S phase 3 clinical trials to multiple sites around the world with an additional 30,000 participants.
November 4, 2020
Wuhan Institute of Biological Products and Sinopharm expand phase 3 clinical trials of their inactive SARS-CoV-2 vaccine to Peru.
November 3, 2020
NVX-CoV2373 phase 3 clinical trials expand with 30000 additional participants in The United States of America, Mexico and Puerto Rico.
November 2, 2020
CureVac’s CVnCoV was generally well tolerated across all tested doses and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation in interim data from an ongoing Phase 1 clinical trial.
November 2, 2020
IIBR-100 , a new replicating COVID-19 vaccine developed by the Israel Institute for Biological Research, starts phase 1/2 clinical trials in Israel.
October 29, 2020
Regeneron’s Casirivimab/Imdevimab significantly reduced viral load and patient medical visits according to prospective results from an ongoing Phase 2/3 clinical trial in the COVID-19 outpatient.
October 28, 2020
Interim analysis of Bamlanivimab , Eli Lilly’s neutralizing antibody, indicated that one of three doses appeared to accelerate the natural decline in SARS-CoV-2 viral load over time, whereas the other doses had not in a New England Journal of Medicine publication of their phase 2 clinical trial.
October 28, 2020
Johnson & Johnson to Resume Phase 3 clinical trial of its COVID-19 Vaccine Candidate, Ad26.COV2.S , in The United States of America.
October 23, 2020
The United States of America Food and Drug Administration authorises restart of the COVID-19 AZD1222 (ChAdOx1 nCoV-19) vaccine phase 3 clinical trial.
October 23, 2020
Remdesivir* , which has been authorized for use on an emergency basis since spring, was officially approved by US regulators as the first treatment for COVID-19.
October 22, 2020
Tocilzumab did not increase patients' chances of survival or help them get better faster according to two studies while a third less definitive trial did find the drug increased the chances of survival. All studies were published in the Journal of the American Medical Association.
October 20, 2020
A new adenoviral-based vaccine, hAd5-S-Fusion+N-ETSD , developed by ImmunityBio, Inc enters phase 1 clinical trials in The United States of America.
October 19, 2020
Entos Pharmaceutical’s Covigenix VAX-001 enters phase 1 clinical trials in Canada, a DNA plasmid vaccine encoding the viral nucleocapsid antigen.
October 19, 2020
Comirnaty (BNT162b2) , one of BioNTech and Pfizer’s COVID-19 vaccine candidates, starts phase 1 clinical trials in Japan.
October 19, 2020
Remdesivir, Hydroxychloroquine, Lopinavir/Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Remdesivir, Hydroxychloroquine, Lopinavir/ Ritonavir* and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Remdesivir, Hydroxychloroquine, Lopinavir* /Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Remdesivir, Hydroxychloroquine*, Lopinavir/Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Remdesivir* , Hydroxychloroquine, Lopinavir/Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Avidaptil treated patients survived 81% of the time beyond 60 days compared to 17% of control patients according to topline efficacy data from a 45-participant open-label prospective study of critically ill COVID-19 patients with severe comorbidities completed by NeuroRx and Relief therapeutics.
October 13, 2020
Phase 3 clinical trials for Johnson & Johnson's COVID-19 vaccine candidate, Ad26.COV2.S , have been put on hold due to an ‘unexplained illness’ observed in a study volunteer
October 13, 2020
Eli Lilly’s phase 3 trial of its monoclonal antibody treatment, Bamlanivimab , has been paused due to potential safety concerns.
October 13, 2020
Novavax’s protein subunit vaccine, NVX-CoV2373 , starts phase 3 clinical trials in the United Kingdom in combination with the seasonal influenza vaccine.
October 12, 2020
A combination of Ivermectin and Doxycycline was shown to improve Early Clinical scores in patients with mild to moderate COVID-19 compared to placebo control in non-peer-reviewed results posted by Dhaka Medical College.
October 9, 2020
Sinovac’s inactive vaccine, CoronaVac , enters phase 3 clinical trials in Turkey with an estimated enrollment of 13,000 participants.
October 9, 2020
A final report by the ACTT-1 Study Group on Remdesivir* in a double-blind, randomized, placebo-controlled trial of 1029 adults who were hospitalized with Covid-19 was published in the New England Journal of Medicine indicating a shortening of the time to recovery and evidence of lower respiratory tract infection compared to placebo control.
October 8, 2020
A small-scale observational study published in the journal Rheumatology indicates that In patients with moderate to severe SARS-CoV-2 pneumonia a combination of Baricitinib* with corticosteroids was associated with greater improvement in pulmonary function when compared with corticosteroids alone.
October 6, 2020
A study published in The Lancet indicates that the antiviral drugs Lopinavir* and Ritonavir*, were not associated with reductions in mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death in patients admitted to hospital with COVID-19.
October 5, 2020
Ridgeback Biotherapeutics and Merck Sharp & Dohme Corp.’s Molnupiravir enters phase 2/3 clinical trials.
October 5, 2020
Results published in Nature of a 60-person subset of BioNTech and Pfizers ongoing Phase 1/2 clinical trials of their BNT162b1 vaccine demonstrates that immunized individuals generate a robust SARS-CoV-2-sepcific antibody and cellular mediated immune response which suggests multiple mechanisms with potential to protect against COVID-19.
September 30, 2020
Merck Sharp & Dohme Corp.’s second COVID-19 vaccine, V590 , enters Phase 1 clinical trials in the United States of America.
September 30, 2020
The Results of Moderna and NIAID’s mRNA-1273 vaccine Phase 1 clinical trial in older adults (56+ years of age) published in the New England Journal of Medicine reveals a robust antibody and cellular immune response in vaccinated individuals.
September 29, 2020
The Universitätsklinikum Hamburg-Eppendorf’s Modified Vaccinia Ankara virus vaccine, MVA-SARS-2-S , enters Phase 1 clinical trials in Germany.
September 29, 2020
Regeneron Pharmaceuticals announces preliminary data from 275 patients in its Phase 1/2/3 clinical trial of its investigational antibody cocktail Casirivimab/Imdevimab showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19.
September 29, 2020
INOVIO’s Phase 2/3 Clinical trial of its COVID-19 vaccine candidate, INO-4800 , has been put on partial clinical hold until questions posed by the U.S. FDA about the candidate and the delivery device (CELLECTRA® 2000) have been satisfactorily addressed. This hold is not due to the occurrence of any adverse events.
September 28, 2020
Chulalongkorn University’s mRNA vaccine, ChulaCov19 , enters Phase 1 clinical trials in Thailand.
September 28, 2020
Vaxart’s non-replicating Ad5 vector SARS-CoV-2 vaccine VXA-CoV2-1 enters Phase I clinical trials in the United States of America.
September 24, 2020
In a press release, FUJIFILM Toyama Chemical Co. announced the results of their Phase 3 clinical trial of Favipiravir* , whereby non-severe pneumonia COVID-19 patients that received the drug had a shorter time to negative conversion of detectable SARS-CoV 2 viral RNA compared to placebo control.
September 23, 2020
AstraZeneca and the University of Oxford’s Phase 3 clinical trial of AZD1222 (ChAdOx1 nCoV-19) has yet to resume in the United States where the FDA is reported to be requesting further data on the two adverse reactions.
September 20, 2020
Roche announced that their Phase 3 study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Tocilizumab* plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care.
September 18, 2020
Eli Lilly announced proof of concept data from an interim analysis of Bamlanivimab , a SARS-CoV-2 neutralizing antibody, in their Phase 2 clinical trial, showing a reduced rate of hospitalization, improved viral clearance, and no drug-related serious adverse events for outpatients in the treatment group.
September 16, 2020
A new multi-peptide based vaccine, CoVac-1 , developed by The University Hospital Tuebingen enters Phase 1 clinical trials in Germany.
September 14, 2020
Imperial College of London Researchers will begin testing the safety and efficacy of both LNP-nCoVsaRNA and The University of Oxford/AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) when administered by inhalation in a 30 patient initial cohort.
September 14, 2020
Initial data released by Eli Lilly and Incyte from the Adaptive COVID-19 Treatment Trial indicates that Baricitinib* in combination with remdesivir reduced time to recovery by approximately one-day and improved patient outcomes at Day 15 when compared with remdesivir alone.
September 14, 2020
The Phase 3 clinical trial of AZD1222 (ChAdOx1 nCoV-19) resumes after the conclusion of an independent review process and following the recommendations of both the independent safety review committee and the United Kingdom Medicines and Healthcare products Regulatory Agency.
September 12, 2020
COVAXX and United Biomedical Inc.’s protein subunit vaccine, UB-612 start Phase 1 clinical trials in Taiwan.
September 11, 2020
Novavax starts Phase 3 clinical trials of its COVID-19 vaccine candidate, NVX-CoV2373 , in the United Kingdom.
September 11, 2020
Vir Biotechnology, Inc and GlaxoSmithKline’s SARS-CoV-2 neutralizing antibody, VIR-7831 , enters phase 2/3 clinical trials.
September 10, 2020
Preclinical data of Pfizers and BioNTech’s RNA-based vaccine, Comirnaty (BNT162b2) , published in the preprint server bioRxiv indicate a robust antibody and T cell response in both mice and non-human primates further validating its ongoing human clinical trials.
September 8, 2020
The University of Oxford and AstraZeneca’s Phase 3 study testing their vaccine candidate, AZD1222 (ChAdOx1 nCoV-19) , was put on hold due to a suspected serious adverse reaction in a United Kingdom trial participant.
September 8, 2020
Sinovac Biotech states that CoronaVac , its inactive coronavirus vaccine candidate, appeared to be safe for older people, while the elicited immune responses were slightly weaker than for younger adults, according to preliminary results from an early to mid-stage trial.
September 7, 2020
CanSino Biologics’ Convidicea (Ad5-nCoV) vaccine starts Phase 3 clinica trials in Russia.
September 7, 2020
The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) starts Phase 3 clinical trials in Russia.
September 7, 2020
Gilead Sciences starts Phase 1/2 clinical trial testing of inhaled Remdesivir* in patients with early-stage SARS-CoV-2 disease.
September 4, 2020
Sanofi and GlaxoSmithKline’s unnamed protein subunit vaccine [ Unnamed Protein Subunit Vaccine - Sanofi/GSK ] enters phase 1/2 clinical trials in the United States.
September 3, 2020
BioNTech’s BNT162b3 enters Phase 1/2 clinical trials in Germany.
September 2, 2020
A meta-analysis of 1703 patients published in The Journal of the American Medical Association demonstrated that administration of systemic corticosteroids [ Corticosteroid Therapy* ] (including dexamethasone, hydrocortisone, or methylprednisolone) was associated with lower 28-day all-cause mortality compared with usual care or placebo.
September 2, 2020
The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) enters Phase 3 clinical trials in Brazil, with an anticipated enrollment of 5000 participants.
September 2, 2020
A publication in the New England Journal of Medicine indicates that Novavax’s NVX-CoV2373 appears to be safe, and elicits both a strong antibody and cellular response against SARS-CoV-2.
September 2, 2020
Results from Sanofi and Regeneron’s Phase 3 clinical trials indicate no statistically significant reduction in hospital stay duration or time to improved clinical outcomes in COVID-19 patients treated with Sarilumab* . The companies do not anticipate conducting further clinical studies using this drug.
September 1, 2020
BeiGene’s anti-coronavirus antibody, BGB DXP593 , enters Phase 1 clinical trials.
September 1, 2020
Pfizers’ SARS-CoV-2 specific antiviral [ PF-07304814 ] enters Phase 1 clinical trials.
September 1, 2020
Novavax’s protein subunit vaccine NVX-CoV2373 enters Phase 2 clinical trials in South Africa.
August 31, 2020
Mabwell Bioscience Co.’s new anti-coronavirus antibody, MW33 , enters Phase 1 clinical trials.
August 31, 2020
Sputnik V (Gam-COVID-Vac) enters Phase 3 clinical trials in Russia, with an expected enrollment of 40,000 participants.
August 28, 2020
QazCovid-in , an inactive viral vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan enters Phase 1/2 clinical trials.
August 28, 2020
An Unnamed Recombinant Vaccine developed by Jiangsu Province Centers for Disease Control and Prevention and West China Hospital enters Phase 1 clinical trials.
August 28, 2020
A gorilla adenovirus-based vaccine, GRAd-COV2 , developed by ReiThera Srl and Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani enters Phase 1 clinical trials in Italy.
August 27, 2020
A second DNA-based vaccine developed by AnGes Inc., AG0302-COVID19 , starts Phase 1/2 clinical trials in Japan.
August 26, 2020
CanSino Biologics Inc. and Beijing Institute of Biotechnology’s adenovirus-based vaccine candidate, Convidicea (Ad5-nCoV) , enters Phase 3 clinical trials in Pakistan.
August 26, 2020
Russia’s second vaccine, EpiVacCorona , enters Phase 1 / 2 clinical trials.
August 25, 2020
A publication in the Journal Clinical Infectious Diseases outlines the first genetic evidence-confirmed case of reinfection with SARS-CoV-2.
August 25, 2020
Convalescent plasma is given Emergency Use Authorization by the U.S. FDA for treatment of patients with COVD-19. Preliminary data suggests a potential beneficial effect, however, solid evidence is lacking.
August 23, 2020
The shingles vaccine, Shingrix , enters Phase 1 clinical trials as a preventative agent in elderly individuals for its hypothesized non-specific immunomodulatory effects.
August 21, 2020
Adimmune’s protein subunit vaccine AdimrSC-2f enters Phase 1 clinical trials in Taiwan.
August 21, 2020
A preprint publication of Phase 1 clinical trial results in the US supports the selection of Pfizer and BioNTech’s Comirnaty (BNT162b2) vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation.
August 20, 2020
A Phase 3 trial of the University of Oxford and AstraZeneca’s SARS-CoV-2 vaccine, AZD1222 (ChAdOx1 nCoV-19) , starts in The United States of America in collaboration with Iqvia Pty Ltd with an expected enrollment of 30,000 participants.
August 18, 2020
CureVac AG’s investigational SARS-CoV-2 mRNA vaccine ( CVnCoV ) enters Phase 2 clinical trials.
August 17, 2020
An interim report of Phase 1/2 trials of the Unnamed Inactive Vaccine - Wuhan Published in the Journal JAMA indicates that patients had a low rate of adverse reactions and demonstrated high neutralizing antibody titers.
August 13, 2020
Preliminary results from an ongoing Phase 1/2 clinical trial published in the journal Nature indicate that BNT162b1 is safe, tolerable, and elicits a robust neutralizing antibody response to SARS-CoV-2 in 45 healthy adult participants.
August 12, 2020
A preprint publication of interim analysis indicated that Colchicine* reduced the length of both, supplemental oxygen therapy and hospitalization in a randomized, double-blinded, placebo-controlled clinical trial of 35 patients with moderate to severe COVID-19.
August 12, 2020
Russia becomes the first country to grant regulatory approval to a coronavirus vaccine, Sputnik V (Gam-COVID-Vac) , prior to its completion of clinical trials.
August 11, 2020
AstraZeneca’s therapeutic combination of monoclonal antibodies against the SARS-CoV-2 spike protein, AZD7442 , enters Phase 1 clinical trials.
August 11, 2020
Sinovac’s inactive vaccine, CoronaVac , was well-tolerated and immunogenic in a preprint publication of Phase 2 clinical trial results that were conducted in a Randomized, Double-blind, and Placebo-controlled fashion in 600 healthy adults.
August 10, 2020
Janssen Vaccine’s Ad26.COV2.S enters Phase 3 clinical trials, with an estimated enrollment of 60,000 participants worldwide.
August 10, 2020
The Corticosteroid Therapy* , Methylprednisolone, was associated with increased ventilator-free days and a higher probability of extubation in a propensity-score matched cohort study of 42 participant pairs published in the journal Clinical Infectious Diseases.
August 9, 2020
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate, NVX-CoV2373 , for local production and commercialization in Japan.
August 7, 2020
Vaccination with NVX-CoV2373 was generally well-tolerated, induced neutralization antibody titers in 100% of participants, and elicited a robust cellular response in Novavax’s 131 participant Phase 1 clinical trial results.
August 4, 2020
Merck’s V591 , a SARS-CoV-2 vaccine candidate that uses an attenuated measles virus as a vector, enters Phase 1 clinical trials.
August 4, 2020
TMV-083 , a vaccine that uses a live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of SARS-CoV-2 enters Phase 1 clinical trials.
August 4, 2020
Eli Lilly and AbCellera’s antibody against the SARS-CoV-2 spike protein, LY3819253, enter Phase 3 clinical trials in the United States.
August 4, 2020
Preliminary results have demonstrated that Aviptadil aided in rapid recovery from respiratory failure in the most critically ill patients with COVID-19 in an ongoing Phase 2/3 clinical trial sponsored by NeuroRx, Inc. and Relief Therapeutics.
August 3, 2020
A study published in Nature shows the SARS-CoV-2 vaccine Ad26.COV2.S elicits a strong immune response that protects against subsequent infection in a non-human primate model.
July 30, 2020
In a press release by Inovio, INO-4800 demonstrated the longest-term protection in non-human primates SARS-CoV-2 challenge model (13 weeks post-vaccination). The immunization also elicited antibodies that neutralize newer viral variants.
July 30, 2020
AZD1222 (ChAdOx1 nCoV-19) elicited a robust immune response in two animal models and prevented pneumonia in a non-human primate model of SARS-CoV-2 infection according to a publication in the journal Nature. However, there was no difference in nasal shedding between vaccinated and control animals.
July 30, 2020
Tocilizumab* failed to improved clinical status in patients with COVID-19 associated pneumonia, or reduced patient mortality in a randomized, double-blind, placebo-controlled phase 3 trial by Roche. The clinical trial program will continue to further explore the drug in other settings, including in combination with an antiviral.
July 29, 2020
The European Union purchases $73.9 million worth of Remdesivir* from Gilead, enough to treat 30,000 patients.
July 29, 2020
Health Canada authorizes the use of Remdesivir* in patients with severe COVID-19 symptoms.
July 28, 2020
BioNTech and Pfizer decide upon Comirnaty (BNT162b2) as their candidate vaccines of choice moving forward in Phase 2/3 clinical trials. This study will include up to 30,000 participants at 120 sites worldwide.
July 27, 2020
MVC-COV1901 , a protein subunit vaccine developed by Medigen Vaccine Biologics Corp. enters Phase 1 clinical trials in Taiwan.
July 27, 2020
Arcturus Therapeutics’ RNA-based vaccine LUNAR-COV19 (ARCT-021) enters Phase 1/2 clinical trials in Singapore.
July 22, 2020
The antiviral drug Favipiravir* demonstrated faster viral clearance compared to the control arm and no severe adverse events in a press release by Glenmark Pharmaceuticals about their Phase 3 clinical trial of 150 individuals with mild to moderate COVID-19.
July 22, 2020
A deal securing up to 600 million doses of Comirnaty (BNT162b2) was reached between The U.S. Government, Pfizer, and BioNTech with an assurance that Americans will receive the vaccine for free.
July 22, 2020
The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) showed an acceptable safety profile as well as elicited both a humoral and cellular immune response in people post-vaccination as demonstrated by a publication in The Lancet. These results support the continued evaluation of this vaccine in Phase III clinical trials.
July 20, 2020
Hospitalized patients who received inhaled Interferon beta-1a* (SNG001) had a 79% lower risk of developing severe disease and were more than twice as likely to recover from COVID-19 as those on placebo in a 101 person Phase II double-blind placebo-controlled trial by Synairgen plc.
July 20, 2020
CanSino’s Convidicea (Ad5-nCoV) vaccine was safe and induced significant immune responses in the majority of recipients after a single immunization according to a publication in The Lancet.
July 20, 2020
The Unnamed Inactive Vaccine - Wuhan developed by The Wuhan Institute of Biological Products enters Phase 3 clinical trials in The United Arab Emirates.
July 18, 2020
The Imperial College’s self-amplifying RNA vaccine, LNP-nCoVsaRNA , moves on to Phase 2 clinical trials in The United Kingdom.
July 17, 2020
Over 100 top scientists and Nobel Laureates signed an open letter to the U.S. NIH calling for the production of unattenuated SARS-CoV-2 to test vaccine efficacy in controlled infection trials. The letter also calls for full transparency on vaccine development and trial participant diversity.
July 16, 2020
KBP-COVID-19 , a vaccine generated by using tobacco plants as bioreactors, enters Phase 1/2 clinical trials.
July 16, 2020
A new inactive viral vaccines, Covaxin , developed by Bharat Biotech International Limited enters Phase 1/2 clinical trials in the Republic of India.
July 15, 2020
Interim Phase 1 results for Modern’a mRNA-1273 vaccine were published in the New England Journal of Medicine, indicating that immunization induced anti–SARS-CoV-2 responses in all participants and no trial-limiting safety concerns were identified.
July 14, 2020
Moderna’s mRNA-1273 enter Phase III clinical trials in the United States of America with a targeted enrollment number of 30,000 participants.
July 14, 2020
The mRNA vaccine candidate Comirnaty (BNT162b2) , developed by Biontech Pharmaceuticals and Pfizer has received ‘fast-track’ designation from the U.S. FDA.
July 13, 2020
The anti-interleukin-6 receptor antibody Tocilizumab* was associated with lower mortality in mechanically ventilated patients suffering from COVID-19 in a single-center, small scale study published in the journal Clinical Infectious Disease. This reduction in mortality, however, came with a higher occurrence of bacterial infections.
July 11, 2020
ZF2001 , the recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters Phase 2 clinical trials in China.
July 10, 2020
Johnson & Johnson’s non-replicating Adenvirus type-26 based vaccine, Ad26.COV2.S , enters Phase 1/2 clinical trials in The United States of America and Belgium.
July 9, 2020
A new DNA-based vaccine developed by AnGes Inc., AG0301-COVID19 , starts Phase 1/2 clinical trials in Japan.
July 9, 2020
Immunization with the repurposed vaccine Bacille Calmette-Guerin* was shown to correlate with reduced mortality according to a study published by The Proceedings of the National Academy of Sciences of the United States of America. Clinical trial results will be required to corroborate these findings.
July 9, 2020
the mRNA-based vaccine mRNA-1273 , developed by Moderna, closes enrolment for its Phase 2 SARS-CoV-2 study.
July 8, 2020
The antiviral drug, Favipiravir* , was demonstrated to expedite the recovery of coronavirus patients in a double-blind placebo control clinical trial conducted by the Bangladesh Society of Medicine.
July 6, 2020
Cadila Healthcare Limited’s DNA plasmid vaccine, ZyCoV-D , enters Phase 1/2 clinical trials in The Republic of India.
July 4, 2020
The World Health Organization stops clinical trials involving (Hydroxy)Chloroquine* and combination Lopinavir* / Ritonavir* as the therapies fail to reduce COVID-19 mortality.
July 4, 2020
The inactive vaccine, CoronaVac , developed by Sinovac Biotech starts Phase III clinical trials in Brazil.
July 2, 2020
The anti-IL-6 antibody, Sarilumab* , was not beneficial in COVID-19 patients requiring mechanical ventilation according to Phase 3 clinical trial results released by Sanofi and Regeneron.
July 2, 2020
The mRNA vaccine candidate, Comirnaty (BNT162b2) , developed by Biontech Pharmaceuticals and Pfizer was shown to be safe, tolerable, and immunogenic in preprint published results of their Phase 1/2 clinical trials.
July 1, 2020
Testing to resume on the antimalarial drug, (Hydroxy)Chloroquine* , to determine if it can prevent SARS-CoV-2 infection.
June 30, 2020
The DNA plasmid vaccine INO-4800 demonstrates Positive Interim Phase 1 Data according to a press release by Inovio Pharmaceuticals.
June 30, 2020
Casirivimab/Imdevimab therapy, Regeneron Pharmaceuticals' anti-spike SARS-CoV-2 monoclonal antibodies enter Phase III clinical trials for prevention of SARS-CoV-2 infection.
June 30, 2020
No clinical benefit was observed from the use of Ritonavir* in hospitalized COVID-19 patients during the University of Oxford’s RECOVERY trial.
June 29, 2020
No clinical benefit was observed from the use of Lopinavir* in hospitalized COVID-19 patients during the University of Oxford’s RECOVERY trial.
June 29, 2020
The Convidicea (Ad5-nCoV) vaccine, developed by CanSino Biologics Inc., gets approval for military use in China.
June 29, 2020
Remdesivir* , Gilead Sciences’ treatment found to have worked in COVID-19 clinical trials, will cost U.S. hospitals $3,120 for the typical patient with private insurance.
June 29, 2020
CoVLP , a virus-like particle vaccine produced by Medicago Inc. enters Phase I clinical trials.
June 29, 2020
BBIBP-CorV , the inactive viral vaccine developed by the Beijing Institute of Biological Products and Sinopharm, was found to be safe and able to generate high titers of antibodies among participants in phase I and II clinical trials according to a company press release.
June 28, 2020
DUR-928 , a drug with a novel mechanism of action developed by Durect, enters Phase 2 clinical trials.
June 26, 2020
an mRNA vaccine, CVnCoV , developed by CureVac and Coalition for Epidemic Preparedness Innovations enters Phase 1 Clinical trials in Germany.
June 26, 2020
M5049 , a small molecule that blocks two innate immune sensors that detect single-stranded RNA from viruses, developed by EMD Serono and Merck enters Phase 2 Clinical trials.
June 26, 2020
The DNA plasmid vaccine, INO-4800 , developed by Inovio Pharmaceuticals in collaboration with International Vaccine Institute and Coalition for Epidemic Preparedness Innovations enters Phases 1/2 in the Republic of Korea.
June 25, 2020
GX-19 , a DNA vaccine expressing SARS-CoV-2 S-protein antigen developed by Genexine, Inc., enters Phase 1/2 clinical trials in the Republic of Korea.
June 24, 2020
A new recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., ZF2001 , enters phase 1 clinical trials in China.
June 24, 2020
News reports indicate that the Unnamed Inactive Vaccine - Wuhan developed by the Wuhan Institute of Biological Products and Sinopharm induced neutralizing antibodies in all vaccinated individuals, and that Phase III clinical trials will start June 23rd in both China and the United Arab Emirates.
June 23, 2020
AZD1222 (ChAdOx1 nCoV-19) starts Phase 1/2 clinical trials to assess safety, immunogenicity, and efficacy in adults with and without HIV in South Africa. This study is a partnership between the University of Witwatersrand, the University of Oxford, the Medical Research Council of South Africa, and the Bill and Melinda Gates Foundation.
June 23, 2020
Inhaled version of antiviral Remdesivir* to start human clinical trials in August according to Gilead Sciences.
June 22, 2020
The Unnamed Inactive Vaccine - Yunnan being developed by The Chinese Academy of Medical Sciences enters Phase II of clinical trials testing.
June 20, 2020
Sputnik V (Gam-COVID-Vac) , a new adenoviral-based vaccine developed by Gamaleya Research Institute, starts phase 1/2 clinical trials in Russia.
June 18, 2020
Preliminary results from the Oxford University RECOVERY trial in the United Kingdom indicates that low-dose Dexamethasone* can reduce mortality by approximately one-third in COVID-19 patients on ventilators and by one-fifth of patients on oxygen.
June 16, 2020
A self-amplifying RNA-based vaccine candidate developed by Imperial College London in partnership with Morningside Ventures named CoVac-1 enters Phase 1/2 clinical trials.
June 15, 2020
The U.S. FDA revokes emergency authorization of (Hydroxy)Chloroquine* for treatment of COVID-19 amid growing evidence of ineffectiveness and the possibility of harmful side effects.
June 15, 2020
Preprint article in medRxiv indicates that Lenzilumab was safe and associated with improved clinical outcomes in high-risk COVID-19 patients with severe and critical pneumonia.
June 14, 2020
AstraZeneca has reached an agreement to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, AZD1222 (ChAdOx1 nCoV-19) , to Germany, France, Italy, and the Netherlands, with deliveries starting by the end of 2020.
June 13, 2020
Sinovac announces no severe adverse events reported and that neutralizing antibodies developed 14 days after the vaccination in its preliminary results of phase 1/2 clinical trial for the Company’s COVID-19 vaccine candidate, CoronaVac .
June 13, 2020
June 12th - A new Unnamed Spike Protein Candidate developed by The University of Queensland enters Phase 1 clinical trials in Australia.
June 12, 2020
Preprint article in medRxiv indicates that the administration of Tocilizumab* is associated with rapid improvement in some clinical indices of those individuals not on ventilation, however, controlled clinical trials are needed to confirm its utility.
June 12, 2020
A novel protein subunit vaccine created by Vaxine and Medytox, COVAX-19 , enters Phase I clinical trials in the US.
June 11, 2020
Moderna moves forward with 100 ug dosage for Phase 3 clinical trial of mRNA-1273 and partners with Lonza to scale up manufacturing potential to generate between 500 million and 1 billion vaccine doses per year.
June 11, 2020
Remdesivir* shows clinical benefit in non-human primates infected with SARS-CoV2, as published in Nature.
June 9, 2020
A publication in the journal Cell indicates that administration of Beijing Institute of Biological Products and Sinopharm’s inactive vaccine, BBIBP-CorV , generates high neutralizing antibody titers and is safe, effective, and stable in numerous animals animal models, including non-human primates.
June 6, 2020
A Statement from the Chief Investigators of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial on (Hydroxy)Chloroquine* indicates no clinical benefit from its use in hospitalized patients with COVID-19.
June 5, 2020
Preprint article in medRxiv indicates that Bacille Calmette-Guerin* vaccination was associated with reduced COVID-19 mortality in level 4:Do Not Travel countries when adjusted for a number of confounding variables.
June 5, 2020
Novavax secures upto $60M from the U.S. Department of Defense to support the production of their NVX-CoV2373 vaccine. The agreement includes a 2020 delivery of 10 million doses for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization if approved by the U.S. FDA.
June 4, 2020
The WHO resumes its COVID-19 (Hydroxy)Chloroquine* study after a publication in The Lancet that questioned the safety and efficacy of the drug was retracted. Questions surrounding data analysis and transparency resulted in the retraction of the publication.
June 3, 2020
A new study published in the New England Journal of Medicine indicates that prophylactic (Hydroxy)Chloroquine* did not prevent Covid-19 or confirmed SARS-CoV-2 infection within 4 days After high-risk or moderate-risk exposure.
June 3, 2020
The Brazilian Health Regulatory Agency approves human trials for Oxford University and AstraZeneca's AZD1222 (ChAdOx1 nCoV-19) . 2000 participants will be considered in Brazil through a study carried out by Oxford University and supported by AstraZeneca.
June 2, 2020
A report released indicates that the Phase 3 clinical trials for Moderna’s COVID-19 experimental vaccine, mRNA-1273 , will start in July with the enrollment of 30,000 individuals in a randomized, placebo-controlled trial.
June 2, 2020
Intravenous Immunoglobulin (IVIG; Octagam) therapy sponsored by Octapharma and Sharp HealthCare enters Phase IV clinical trials for COVID-19.
June 2, 2020
A new Unnamed Inactive Vaccine SARS-CoV-2 vaccine being developed by the Chinese Academy of Medical Sciences in collaboration with West China Second University Hospital and Yunnan Center for Disease Control and Prevention enters Phase 1/2.
June 2, 2020
Results released by Gilead indicate that in a Phase III trial, Remdesivir* treatment resulted in significantly greater clinical improvement versus standard of care treatment alone.
June 1, 2020
The immunosuppressive/antiviral Merimepodib* by ViralClear Pharmaceuticals enters Phase II clinical trials against COVID-19.
June 1, 2020
Emergent BioSolutions enters into a $628 million contract with the US government to boost manufacturing capacity for a COVID-19 vaccine.
June 1, 2020
mRNA-1273 , the joint vaccine initiative by Moderna, NIAID, and BARDA, enters Phase 2 clinical trials for COVID-19.
May 28, 2020
The spike protein subunit vaccine by Clover Biopharmaceutical, SCB-2019 , enters Phase 1 clinical trials against COVID-19.
May 28, 2020
France’s health ministry cancels the usage of (Hydroxy)Chloroquine* as a treatment to patients suffering severe forms of COVID-19.
May 27, 2020
The United Kingdom National Health Service follows suit behind The United States and Japan and authorizes the use of Remdesivir* for people with coronavirus infection after a publication in The New England Journal of Medicine indicates it can cut recovery time by about four days.
May 26, 2020
The World Health Organization suspends testing of (Hydroxy)Chloroquine* as a treatment for coronavirus after publication in The Lancet suggests drug could increase the risk of patients dying from COVID-19.
May 25, 2020
Novavax administrates the NVX-CoV2373 vaccine to the first participants in Phase 1 clinical trial. Phase 2 planned to begin following successful Phase 1 results. On May 11, Novavax secured a $388M grant from CEPI (a Bill & Melinda Gates Foundation-backed vaccine development coalition).
May 25, 2020
Sinovac Biotech Co. has received $15M in funding to advance the development of its Covid-19 vaccine candidate, CoronaVac .
May 25, 2020
CanSino Biologics’ Convidicea (Ad5-nCoV) vaccine starts Phase 1/2 clinical trials in Canada against COVID-19 in collaboration with the Canadian Center for Vaccinology.
May 22, 2020
Phase 1 results for CanSino Biologics’ Convidicea (Ad5-nCoV) vaccine published in The Lancet indicate it was tolerable and immunogenic in humans and warrants further clinical trials testing.
May 22, 2020
AstraZeneca/The University of Oxford vaccine AZD1222 (ChAdOx1 nCoV-19) starts Phase 2 / 3 clinical trials for COVID-19.
May 22, 2020
The INOPulse Delivery System by Bellerophon Therapeutics enters Phase 2 clinical trials for COVID-19.
May 22, 2020
AZD1222 (ChAdOx1 nCoV-19) , developed by the University of Oxford and licensed to AstraZeneca secures $1.2 billion backing from U.S Department of Health for accelerated development.
May 21, 2020
Publication in Nature Communications demonstrates robust antibody and cellular immunity elicited by Inovio's INO-4800 vaccine in preclinical models.
May 20, 2020
Inovio Pharmaceuticals press release announces positive interim Phase 1 data for their INO-4800 vaccine.
May 20, 2020
The elastase inhibitor MPH996* starts Phase 2 clinical trials for COVID-19 in Egypt.
May 20, 2020
Inovio Pharmaceutical's INO-4800 vaccine elicits robust immune response in preclinical models as shown in Nature Communications publication.
May 20, 2020
The C3 complement inhibitor AMY-101 sponsored by Amyndas Pharmaceuticals starts Phase 2 clinical trials for severe COVID-19.
May 20, 2020
Atea Pharmaceuticals' AT-527 , a novel modified guanosine nucleotide prodrug, starts Phase 2 for COVID-19.
May 20, 2020
ABX464 , a small molecule inhibitor of the cap binding complex sponsored by Abivax enters Phase 2 / 3 clinical trials for COVID-19.
May 19, 2020
Moderna press release announces positive interim Phase 1 data for its mRNA Vaccine, mRNA-1273 .
May 18, 2020
Health Canada approves human testing for CanSino Biologics's Convidicea (Ad5-nCoV) vaccine. Trial will be conducted out of the Canadian Centre for Vaccinology at Dalhousie University.
May 18, 2020
Molnupiravir , an oral nucleoside analog sponored by Ridgeback Biotherapeutics and Merck, enters Phase I clinical trials for COVID-19.
May 18, 2020
The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Ravulizumab into Phase 4 clinical trials.
May 18, 2020
The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Baricitinib* into Phase 4 clinical trials.
May 18, 2020
Implicit Bioscience and the University of Washington’s anti-CD14 antibody, IC14 , enters Phase 2 clinical trials for COVID-19.
May 18, 2020
The anti-malarial Artemisinin* enters Phase 2 clinical trials for COVID-19.
May 15, 2020
AV-COVID-19 is a new dendritic cell vaccine in Phases 1/2 clinical trials for COVID-19.
May 13, 2020
Ifenprodil , an NDMA inhibitor by Algernon Pharmaceuticals and Novatech starts Phase 2 / 3 clinical trials for COVID-19.
May 11, 2020
The vaccine for tuberculosis, Bacille Calmette-Guerin* is now in consideration for COVID-19. Undergoing clinical Phases 3/4 trials.
April 20, 2020
Subscribe to Updates Enter your email to get alerted with major weekly updates.
Email
How would you describe yourself?
Vaccines
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
216
+6
TOTAL

122 in preclinical development

92 in human trials

Vaccine Candidates Development Progress

Vaccine CANDIDATES

PittCoVacc
DPX-COVID-19
AdCOVID
CoroFlu
+117 unnamed
Preclinical
122
Phase I
87
Phase II
55
Phase III
27
Phase IV
7

Legend

Completed
In trials
Vaccine CandidatesClick on name for additional information
  ↓/↑Name  ↓/↑Organization  ↓/↑Technology  ↓/↑Stage  Countries  ↓/↑Clinical Trial #
Shenzhen Geno-Immune Medical Institute
Modified APCPhase I/II
China
NCT04276896
Multiple Organizations
RNA-based vaccinePhase I/II/III/IV
United States of America
NCT04283461
and 12 more
Multiple Organizations
Non-replicating viral vectorPhase I/II/III
China
Canada
NCT04313127
and 8 more
Multiple Organizations
Inactivated virusPhase I/II/III/IV
Global
NCT04352608
and 17 more
Multiple Organizations
DNA-basedPhase I/II/III
Global
NCT04336410
and 2 more
Multiple Organizations
Inactivated virusPhase I/II/III
China
ChiCTR2000031809
and 3 more
Multiple Organizations
Inactivated virusPhase I/II/III
China
ChiCTR2000032459
and 4 more
Multiple Organizations
DNA-basedPhase I
Canada
NCT04334980
updated
Multiple Organizations
RNA-based vaccinePhase I/II/III/IV
Germany
Global
EudraCT 2020-001038-36
and 23 more
Novavax,
Takeda
Protein subunitPhase I/II/III
Global
NCT04368988
and 5 more
Shenzhen Geno-Immune Medical Institute
Modified APCPhase I
China
NCT04299724
Unnamed
Saiba GmbH
Virus Like ParticlePreclinical Phase
Medicago Inc.
Virus Like ParticlePhase I/II/III
Global
NCT04450004
and 2 more
Unnamed
Imophoron Ltd,
Bristol University's Max Planck Centre
Virus Like ParticlePreclinical Phase
Unnamed
Doherty Institute
Virus Like ParticlePreclinical Phase
Unnamed
Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine,
Chile*
UnknownPreclinical Phase
Unnamed
Emergex Vaccines,
George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)*
UnknownPreclinical Phase
Unnamed
VBI Vaccines,
National Research Council of Canada
UnknownPreclinical Phase
Unnamed
SmartPharm Therapeutics,
Sorrento Therapeutics
UnknownPreclinical Phase
Unnamed
HaloVax (Voltron Therapeutics),
The Vaccine & Immunotherapy Center at the Massachusetts General Hospital
UnknownPreclinical Phase
Unnamed
ISR Immune System Regulation
UnknownPreclinical Phase
Unnamed
ImmunoPrecise
UnknownPreclinical Phase
Unnamed
Tulane University
UnknownPreclinical Phase
Unnamed
SK Biosciences
UnknownPreclinical Phase
Unnamed
Vir Biotechnology,
GSK
UnknownPreclinical Phase
Unnamed
Precision Vaccines Program at Boston Children's Hospital
UnknownPreclinical Phase
Kentucky BioProcessing,
Inc.
Protein subunitPhase I/II
United States of America
United Kingdom
NCT04473690
Unnamed
Universite Laval
UnknownPreclinical Phase
Multiple Organizations
Protein subunitPhase I/II/III
United States of America
Taiwan
NCT04545749
and 2 more
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
Centro Nacional Biotecnologia (CNB-CSIC),
Spain
RNA-based vaccinePreclinical Phase
Unnamed
University of Tokyo,
Daiichi-Sankyo
RNA-based vaccinePreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Arcturus Therapeutics, Inc.,
Duke-NUS
RNA-based vaccinePhase I/II
United States of America
Republic of Singapore
NCT04480957
and 2 more
Imperial College London,
Morningside Ventures
RNA-based vaccinePhase I/II
United Kingdom
China
IRAS-Number: 279315
and 1 more
CureVac AG,
Coalition for Epidemic Preparedness Innovations (CEPI)
RNA-based vaccinePhase I/II/III
Germany
NCT04449276
and 3 more
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
BIOCAD
RNA-based vaccinePreclinical Phase
Unnamed
Sanofi Pasteur,
Translate Bio
RNA-based vaccinePreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
GeneOne Life Science,
Houston Methodist
RNA-based vaccinePreclinical Phase
Unnamed
Zydus Cadila
Replicating viral vectorPreclinical Phase
Multiple Organizations
Replicating viral vectorPhase I
Global
NCT04497298
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
ExpreS2ion
Protein subunitPreclinical Phase
Unnamed
WRAIR,
USAMRIID
Protein subunitPreclinical Phase
Unnamed
National Institute of Infectious Disease,
Japan
Protein subunitPreclinical Phase
Unnamed
Osaka University / BIKEN / National Institutes of Biomedical Innovation,
Japan
Protein subunitPreclinical Phase
Multiple Organizations
Protein subunitPhase I/II/III
China
NCT04405908
and 1 more
Unnamed
Vaxil Bio
Protein subunitPreclinical Phase
Unnamed
Biological E Ltd
Protein subunitPreclinical Phase
Unnamed
AJ Vaccines
Protein subunitPreclinical Phase
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
Generex,
EpiVax
Protein subunitPreclinical Phase
Unnamed
EpiVax,
University of Georgia
Protein subunitPreclinical Phase
PittCoVacc
University of Pittsburgh
Protein subunitPreclinical Phase
United States of America
Unnamed
University of Cambridge,
DIOSynVax
Protein subunitPreclinical Phase
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Sanofi Pasteur,
GlaxoSmithKline
Protein subunitPhase I/II
Global
NCT04537208
and 1 more
Unnamed
Heat Biologics (Zolovax),
University of Miami
Protein subunitPreclinical Phase
Multiple Organizations
Protein subunitPhase I
Global
ACTRN12620000674932
and 1 more
Unnamed
Baylor College of Medicine
Protein subunitPreclinical Phase
Unnamed
iBio,
CC-Pharming
Protein subunitPreclinical Phase
Unnamed
St. Petersburg Scientific Research Institute of Vaccines and Serums
Protein subunitPreclinical Phase
Unnamed
VIDO-InterVac,
University of Saskatchewan
Protein subunitPreclinical Phase
Unnamed
Flow Pharma
Protein subunitPreclinical Phase
Unnamed
OncoGen
Protein subunitPreclinical Phase
Unnamed
MIGAL Galilee Research Institute
Protein subunitPreclinical Phase
Unnamed
University of Alberta
Protein subunitPreclinical Phase
DPX-COVID-19
IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University / Izaak Walton Killam Health Center/ Nova Scotia Health Authority,
Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada
Protein subunitPreclinical Phase
Canada
Unnamed
GeoVax,
BravoVax
Non-replicating viral vectorPreclinical Phase
updated
Multiple Organizations
Non-replicating viral vectorPhase I/II/III
United States of America
NCT04436276
and 7 more
Unnamed
ReiThera
Non-replicating viral vectorPreclinical Phase
Unnamed
ImmunityBio,
NantKwest
Non-replicating viral vectorPreclinical Phase
Unnamed
DZIF - German Center for Infection Research
Non-replicating viral vectorPreclinical Phase
AdCOVID
Altimmune,
University of Alabama at Birmingham
Non-replicating viral vectorPreclinical Phase
United States of America
Unnamed
Greffex
Non-replicating viral vectorPreclinical Phase
Vaxart
Non-replicating viral vectorPhase I
United States of America
NCT04563702
Unnamed
Centro Nacional Biotecnologia (CNB-CSIC),
Spain
Non-replicating viral vectorPreclinical Phase
Unnamed
University of Manitoba
Non-replicating viral vectorPreclinical Phase
Unnamed
DZIF - German Center for Infection Research
Non-replicating viral vectorPreclinical Phase
Unnamed
Tonix Pharma,
Southern Research
Non-replicating viral vectorPreclinical Phase
Unnamed
BIOCAD,
IEM
Non-replicating viral vectorPreclinical Phase
Unnamed
IAVI,
Batavia
Non-replicating viral vectorPreclinical Phase
Unnamed
The University of Hong Kong
Non-replicating viral vectorPreclinical Phase
Unnamed
University of Western Ontario
Non-replicating viral vectorPreclinical Phase
Unnamed
Valneva,
Dynavax*
Inactivated virusPreclinical Phase
Unnamed
Sinovac,
Dynavax
Inactivated virusPreclinical Phase
UnnamedMultiple Organizations
Inactivated virusPreclinical Phase
Unnamed
Codagenix,
Serum Institute of India
Inactivated virusPreclinical Phase
CoroFluMultiple Organizations
Inactivated virusPreclinical Phase
United States of America
Republic of India
UnnamedMultiple Organizations
DNA-basedPreclinical Phase
Unnamed
OPENCORONA - Cobra Biologics,
Karolinska Institute
DNA-basedPreclinical Phase
AnGes, Inc.,
Japan Agency for Medical Research and Development
DNA-basedPhase I/II
NCT04463472
AnGes, Inc.,
Japan Agency for Medical Research and Development
DNA-basedPhase I/II/III
NCT04527081
and 1 more
Zydus Cadila,
Cadila Healthcare Limited
DNA-basedPhase I/II
CTRI/2020/07/026352
UnnamedMultiple Organizations
DNA-basedPreclinical Phase
Unnamed
BioNet Asia
DNA-basedPreclinical Phase
Unnamed
University of Waterloo
DNA-basedPreclinical Phase
Multiple Organizations
RepurposedPhase III/IV
Global
NCT04357028
and 2 more
Immunitor LLC
Inactivated virusPhase I/II
Canada
NCT04380532
Multiple Organizations
Modified APCPhase I/II
United States of America
NCT04386252
and 2 more
Multiple Organizations
Non-replicating viral vectorPhase I/II/III/IV
United Kingdom
NCT04324606
and 20 more
Multiple Organizations
RepurposedPhase II/III/IV
Global
NCT04328441
and 29 more
Multiple Organizations
Inactivated virusPhase I/II/III
China
NCT04412538
and 2 more
Multiple Organizations
Protein subunitPhase I
Global
NCT04428073
and 1 more
Multiple Organizations
Non-replicating viral vectorPhase I/II/III
Russia
NCT04437875
and 11 more
Immunovative Therapies, Ltd.,
Mirror Biologics, Inc.
OtherPhase I/II
United States of America
NCT04441047
Multiple Organizations
RepurposedPhase III
Canada
United Kingdom
NCT04442048
Altimmune,
Inc.
RepurposedPhase II
United States of America
NCT04442230
Genexine,
Inc.
DNA-basedPhase I/II
NCT04445389
and 1 more
Multiple Organizations
RepurposedPhase III/IV
Global
NCT04445428
and 2 more
Inmunotek S.L.,
BioClever 2005 S.L.
RepurposedPhase III
Mexico
NCT04452643
Fundació Institut Germans Trias i Pujol
RepurposedPhase N/A
NCT04453488
Multiple Organizations
Inactivated virusPhase I/II/III
Republic of India
NCT04471519
and 1 more
updated
Medigen Vaccine Biologics Corp.
Protein subunitPhase I/II
Taiwan
NCT04487210
and 2 more
Multiple Organizations
Protein subunitPhase I/II/III
China
NCT04445194
and 3 more
Multiple Organizations
RNA-based vaccinePhase I
China
ChiCTR2000034112
Merck Sharp & Dohme Corp.
Replicating viral vectorPhase I
United States of America
NCT04498247
Adimmune Corporation
Protein subunitPhase I
Taiwan
NCT04522089
Oklahoma Medical Research Foundation,
University of Oklahoma
RepurposedPhase I
United States of America
NCT04523246
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Protein subunitPhase I/II/III
Russia
NCT04527575
and 1 more
Multiple Organizations
Inactivated virusPhase I/II/III
NCT04530357
and 1 more
ReiThera Srl,
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Non-replicating viral vectorPhase I/II/III
NCT04528641
and 1 more
Jiangsu Province Centers for Disease Control and Prevention,
West China Hospital
Protein subunitPhase I/II
China
NCT04530656
and 2 more
University Hospital Tuebingen
Protein subunitPhase I
Germany
NCT04546841
Multiple Organizations
RNA-based vaccinePhase I
NCT04566276
Entos Pharmaceuticals Inc.,
Canadian Institutes of Health Research
DNA-basedPhase I
Canada
NCT04591184
ImmunityBio,
Inc.
Non-replicating viral vectorPhase I
United States of America
NCT04591717
and 2 more
Multiple Organizations
Replicating viral vectorPhase I
Germany
NCT04569383
Israel Institute for Biological Research
Replicating viral vectorPhase I/II
NCT04608305
Codagenix,
Inc
Replicating viral vectorPhase I
United Kingdom
NCT04619628
Providence Health & Services,
OncoSec Medical Incorporated
DNA-basedPhase I
United States of America
NCT04627675
Multiple Organizations
Protein subunitPhase I/II
China
NCT04636333
and 1 more
Jiangsu Province Centers for Disease Control and Prevention
Non-replicating viral vectorPhase I
China
NCT04568811
City of Hope Medical Center,
National Cancer Institute
Replicating viral vectorPhase I
United States of America
NCT04639466
GeneOne Life Science,
Inc.
DNA-basedPhase I/II
NCT04673149
Valneva Austria GmbH,
National Institute for Health Research, United Kingdom
Inactivated virusPhase I/II
United Kingdom
NCT04671017
Cellid Co.,
Ltd.
Non-replicating viral vectorPhase I/II
NCT04666012
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Protein subunitPhase I/II
NCT04683484
University Medical Center Groningen,
Akston Biosciences Corporation
Protein subunitPhase I/II
Netherlands
NCT04681092
Altimmune,
Inc.
Non-replicating viral vectorPhase I
United States of America
NCT04679909
Takeda
Protein subunitPhase I/II
NCT04677660
updated
Health Institutes of Turkey,
TC Erciyes University
Inactivated virusPhase I/II
NCT04691947
and 1 more
Multiple Organizations
Protein subunitPhase I/II
Canada
NCT04702178
Multiple Organizations
Protein subunitPhase I/II
NCT04750343
and 1 more
Multiple Organizations
DNA-basedPhase I
Australia
NCT04742842
Multiple Organizations
Inactivated virusPhase I/II
China
NCT04758273
and 1 more
GlaxoSmithKline
RNA-based vaccinePhase I
United States of America
NCT04758962
Bharat Biotech International Limited
Non-replicating viral vectorPhase I
Republic of India
NCT04751682
SK Bioscience Co.,
Ltd.
Protein subunitPhase I
NCT04760743
Providence Therapeutics Holdings Inc.
RNA-based vaccinePhase I
Canada
NCT04765436
Mahidol University,
The Government Pharmaceutical Organization
Replicating viral vectorPhase I/II
NCT04764422
National Institute of Allergy and Infectious Diseases
Non-replicating viral vectorPhase I
United States of America
NCT04776317
National Institute of Allergy and Infectious Diseases
RNA-based vaccinePhase I
United States of America
NCT04776317
VBI Vaccines Inc.
Virus Like ParticlePhase I/II
Canada
NCT04773665
Takis,
Rottapharm Biotech
DNA-basedPhase I/II
NCT04788459
EuBiologics Co.,Ltd
Protein subunitPhase I/II
NCT04783311
Multiple Organizations
Protein subunitPhase I
United States of America
NCT04784767
Meissa Vaccines,
Inc.
Replicating viral vectorPhase I
United States of America
NCT04798001
Sanofi Pasteur
RNA-based vaccinePhase I/II
United States of America
NCT04798027
Multiple Organizations
Virus Like ParticlePhase I
NCT04818281
Jiangsu Rec-Biotechnology Co.,
Ltd.
Protein subunitPhase I
China
NCT04818801
ModernaTX,
Inc.
RNA-based vaccinePhase I
United States of America
NCT04813796
The University of Hong Kong
Replicating viral vectorPhase I
China
NCT04809389
new
Daiichi Sankyo Co.,
Ltd.
RNA-based vaccinePhase I/II
NCT04821674
Merck Sharp & Dohme Corp.
Replicating viral vectorPhase I
United States of America
NCT04569786
Therapeutic Drugs
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
506
+1
TOTAL

87 in preclinical development

419 in human trials